Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Fate Therapeutics Inc is a biotechnology business based in the US. Fate Therapeutics shares (FATE) are listed on the NASDAQ and all prices are listed in US Dollars. Fate Therapeutics employs 356 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$58.16|
|52-week range||$42.64 - $121.16|
|50-day moving average||$62.89|
|200-day moving average||$77.08|
|Wall St. target price||$108.79|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.34|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-2.37%|
|1 month (2021-09-27)||-9.63%|
|3 months (2021-07-27)||-27.43%|
|6 months (2021-04-27)||-37.14%|
|1 year (2020-10-26)||24.01%|
|2 years (2019-10-25)||287.48%|
|3 years (2018-10-26)||333.06%|
|5 years (2016-10-26)||2,484.89%|
|Revenue TTM||$48 million|
|Gross profit TTM||$-94,189,000|
|Return on assets TTM||-11.82%|
|Return on equity TTM||-34.58%|
|Market capitalisation||$5.6 billion|
TTM: trailing 12 months
There are currently 11.4 million Fate Therapeutics shares held short by investors – that's known as Fate Therapeutics's "short interest". This figure is 3.4% down from 11.8 million last month.
There are a few different ways that this level of interest in shorting Fate Therapeutics shares can be evaluated.
Fate Therapeutics's "short interest ratio" (SIR) is the quantity of Fate Therapeutics shares currently shorted divided by the average quantity of Fate Therapeutics shares traded daily (recently around 951331.80300501). Fate Therapeutics's SIR currently stands at 11.98. In other words for every 100,000 Fate Therapeutics shares traded daily on the market, roughly 11980 shares are currently held short.
However Fate Therapeutics's short interest can also be evaluated against the total number of Fate Therapeutics shares, or, against the total number of tradable Fate Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fate Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Fate Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1675% of the tradable shares (for every 100,000 tradable Fate Therapeutics shares, roughly 168 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Fate Therapeutics.
Find out more about how you can short Fate Therapeutics stock.
We're not expecting Fate Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Fate Therapeutics's shares have ranged in value from as little as $42.64 up to $121.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fate Therapeutics's is 1.7291. This would suggest that Fate Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.